Last update 21 Nov 2024

Anti-COVID-19 Immune Globulin (Human)(Grifols Therapeutics)

Overview

Basic Info

Drug Type
Immunoglobulin
Synonyms
C19-IG 20%
Target-
Mechanism-
Therapeutic Areas
Infectious DiseasesRespiratory DiseasesOther Diseases
Active Indication-
Inactive Indication
COVID-19Severe acute respiratory infectionSevere Acute Respiratory Syndrome
Originator Organization
Grifols Therapeutics LLC
Active Organization-
Inactive Organization
Grifols Therapeutics, Inc.
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Anti-COVID-19 Immune Globulin (Human)(Grifols Therapeutics)
NCT04847141 / TerminatedPhase 3
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of Anti-COVID-19 Immune Globulin (Human) 20% (C19-IG 20%) Versus Placebo in Asymptomatic Ambulatory Outpatients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
100 Clinical Results associated with Anti-COVID-19 Immune Globulin (Human)(Grifols Therapeutics)
Login to view more data
100 Translational Medicine associated with Anti-COVID-19 Immune Globulin (Human)(Grifols Therapeutics)
Login to view more data
100 Patents (Medical) associated with Anti-COVID-19 Immune Globulin (Human)(Grifols Therapeutics)
Login to view more data
100 Deals associated with Anti-COVID-19 Immune Globulin (Human)(Grifols Therapeutics)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19Phase 3
ES
Grifols Therapeutics, Inc.
28 Apr 2021
Severe acute respiratory infectionPhase 3
ES
Grifols Therapeutics, Inc.
28 Apr 2021
Severe Acute Respiratory SyndromePhase 3
ES
Grifols Therapeutics, Inc.
28 Apr 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT04847141 (COVID-19, CTgov)
Phase 3
COVID-19 | Severe acute respiratory infection | Severe Acute Respiratory Syndrome
465
0.9% sodium chloride+C19-IG 20%
(C19-IG 20% 1 g)
zepnlduoiy(ewyomxnfgm) = xxgqmcfvxf vwrqoywzzz (jmydbnzons, yxeikpqvlv - moyznkncfu)
View more
-
05 Dec 2022
(C19-IG 20% 2 g)
zepnlduoiy(ewyomxnfgm) = wbuuknquol vwrqoywzzz (jmydbnzons, zzyoervcas - ygsgobftdo)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free